Sheng He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sheng He has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Bijun Luo
Department of Anesthesiology The Maternal and Child Health Care Hospital of Guangxi Zhuang Autonomous Region Nanning China
1 shared publication- Enqiang Chang
Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Guangxi Clinical Research Center for Anesthesiology, Guangxi, China
1 shared publication Guanghua Tao
Department of Anesthesiology Xichang People's Hospital Xichang China
1 shared publication- Linghui Pan
Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning, China
1 shared publication Xiaoting Liao
Department of Anesthesiology Guangxi Medical University Cancer Hospital, Guangxi Clinical Research Center for Anesthesiology Nanning China
1 shared publication
Latest Publications
- Open Access
- 20 January 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (7) , e70164
Agrimoniin Alleviates Ferroptosis in Cold‐Stored DCD Liver Grafts Through Activation of the Nrf‐2 Pathway
Liver grafts from donation‐after‐cardiac‐death (DCD) are vulnerable to ischemia–reperfusion injury, which compromises graft function after transplantation. Agrimoniin has been shown to possess antioxidant and anti‐inflammatory properties, making it a potential therapeutic agent for organ preservation. This study investigated whether supplementing agrimoniin to the University of Wisconsin (UW) cold storage solution protected liver grafts from DCD rats or cold preserved human liver cell lines (QSG‐7701 and HepG2). Agrimoniin supplementation significantly reduced oxidative damage, alleviated ferroptosis, and mitigated liver injury by activating the Nrf‐2 pathway, both in vivo and in vitro. These findings suggest that ferroptosis is a mediator in DCD liver injury, and agrimoniin, through its activation of the Nrf‐2 pathway, may be an effective therapeutic agent for enhancing liver graft preservation and improving outcomes in DCD liver transplantation.
- 20 January 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (7) , e70164
Open AccessAgrimoniin Alleviates Ferroptosis in Cold‐Stored DCD Liver Grafts Through Activation of the Nrf‐2 Pathway
Liver grafts from donation‐after‐cardiac‐death (DCD) are vulnerable to ischemia–reperfusion injury, which compromises graft function after transplantation. Agrimoniin has been shown to possess antioxidant and anti‐inflammatory properties, making it a potential therapeutic agent for organ preservation. This study investigated whether supplementing agrimoniin to the University of Wisconsin (UW) cold storage solution protected liver grafts from DCD rats or cold preserved human liver cell lines (QSG‐7701 and HepG2). Agrimoniin supplementation significantly reduced oxidative damage, alleviated ferroptosis, and mitigated liver injury by activating the Nrf‐2 pathway, both in vivo and in vitro. These findings suggest that ferroptosis is a mediator in DCD liver injury, and agrimoniin, through its activation of the Nrf‐2 pathway, may be an effective therapeutic agent for enhancing liver graft preservation and improving outcomes in DCD liver transplantation.